Endocrine Abstracts

Context: There is scant evidence of tumoral mass reduction in Thyrotropin-secreting pituitary adenomas (TSPA) treated with long-acting somatostatin analogs. There are no reports that evaluate TSPA shrinkage after deep subcutaneous (sc) Lanreotide-ATG (L-ATG) therapy.Objective: The primary objective was to observe if L-ATG could reduce TSPA tumor mass.Methods: A literature review on the subject was made. The biochemical and radiolog...

Objective: To find consensus on issues that may raise clinical doubts in the management of patients with acromegaly in Spain.Methods: Nominal group and Delphi methodology was followed. Four experts on acromegaly were selected, who defined important clinical questions in the management of acromegaly. A set recommendations were proposed to solve these questions. Subsequently, a group of 30 additional endocrinologits from all over Spain was selected accordi...

Introduction: Human recombinant growth hormone (hrGH) treatment in adult patients with GH deficiency (GHD) has an important interindividual variability and several factors can influence it. The aims of the study were: i)- to analyze the genotype of GHR regarding exon 3 deletion (d3-GHR) in a serie of adult patients with GHD; ii)- to assess the effect of d3-GHR on initial IGF1 levels; iii)- to evaluate if d3-GHR and/or initial IGF1 levels were associated with adverse effects an...

Most kindreds of familial isolated pituitary adenomas (FIPA) with mutated AIP develop somatotropinomas, characterized by an aggressive clinical phenotype including early age at diagnosis, large tumours and frequent invasiveness. In non-family cases, the prevalence of AIP mutations in pituitary adenomas is lower than 10%. There is no information of AIP prevalence in isolated somatotropinomas characterized by poor response to conventional treatment.Aim: To...

Recent studies have shown that the co-administration of lanreotide (lan) with pegvisomant (peg) was able to normalise IGF1 secretion in patients with acromegaly who were partial responders to somatostatin analogues (SSAs).Fifty seven subjects with acromegaly (mean age 51.6±12.7 years) not previously controlled by SSAs (either treated by SSAs for at least 6 months with IGF1 > ULN, or on peg for at least 3 months) with IGF1 > 1.2 ULN (n...

Papillary thyroid carcinoma (PTC), the most frequent thyroid cancer, has low proliferation but no apoptosis, presenting frequent lymph-node metastasis (Ordonez et al., 2004).SMAD3 has two opposite phosphorylation sites: the TGF-βRI–induced C-terminal Serine SMAD3 phosphorylation and the phosphorylation induced by CDK2 (T8, T179 and S213) and ERK (T179, S204, S208) (Wang et al. 2005, Matsuura et al. 2005).<p class=...

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...

ObjectivesTo present the results of our series of endoscopic surgery of PA, performed in a third level hospital by an experienced team.MethodsRetrospective review of PA undergoing endoscopic surgery between 2011 – 2018 in our institution. Clinical variables and radiological characteristics and outcomes were collected at diagnosis, before surgery and for an average of 4.8 years of postoperative follow-up....

Background: T2-weighted magnetic resonance imaging (MRI) signal has been recently linked with a better tumor response to pasireotide treatment in patients with acromegaly (ACRO). Our aim was to evaluate the prevalence of this radiological feature and its association to therapeutic outcomes in a large cohort of ACRO patients treated with pasireotide.Methods: A retrospective multicentre study was performed in 15 Spanish tertiary university hospitals includ...

Context: There is no data on mortality of acromegaly diagnosed in the elderly. Objective: To compare clinical characteristics, GH-related comorbidities, therapeutic approaches and mortality of patients diagnosed before or after 2010 and to assess overall mortality compared with the general Spanish population. Setting: Spanish tertiary care centers.Design, Patients, and Methods: Retrospective evaluation of 118...